Finally, another piece of the puzzle emerges in depression
As the medical field has received many technical innovations over the years, psychiatry and psychology has been left with surprisingly little. Now, with the EDOR-test, a new and objective method for use in psychiatry and psychology research and clinical routine is available.
What is EDOR® Test and what does it do?
EDOR Test is a psychophysiological test using electrodermal reactions evoked by the brain to repeated neutral sound signals in order to analyse habituation patterns. Normally, reactions to repeated neutral stimuli gradually subside over time as the brain learns and builds a memory model of the events. In one patient group, reactions to the signals stops very quickly. These patients are classified as hyporeactive. Hyporeactivity in turn, have been shown to be a state associated with a more challenged course of disease in patients with depression.
Hyporeactivity in depression
Hyporeactivity is a state that is stable over time and remains after the depression is treated. Depressed hyporeactive patients have increased vulnerability to relapses in depression, suicide attempts, and suicide among adults.
Although hyporeactivity is associated to increased risks in depression, it is independent of common factors commonly used in psychiatric care, such as:
- Symptoms and depth of depression (BDI, MADRS)
- Traits (STAI-Trait) anxiety
- Serotonin activity (5-HIAA in liquor)
- Age and gender in adults
- Language and cultural background
It functions as a biomarker, adding vital biological information to the overall assessment of the patient and should be used as a complement in this process. With this addition, a higher precision in the short and long -term planning of treatment and care is possible to achieve.
The Board and CEO of Emotra AB herewith present the year-end report for the financial year 2019. 200221- Year-end report [...]
Due to the trading volumes seen in shares in Emotra and the large share price rise in its wake, the [...]
The Company is now taking an important first step for the new indication area for EDOR® Test – depression relapse. [...]
At the end of 2019, Emotra AB (“Emotra”) were interviewed by the management team at AstraZeneca BioVentureHub, after which we [...]